TransMedics price target raised to $120 from $95 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics to $120 from $95 and keeps an Overweight rating on the shares after the company reported Q1 results that “handily beat on the top- and bottom-lines.” The firm expects the company will continue to deliver “some of the best top-line growth in medtech” and that management’s continued focus on profitability “will also be welcomed by investors,” the analyst says investors in a post-earnings note.